Market Cap
$1.1B
AKTS
Aktis Oncology, Inc.
$18.26 ▼ -1.40%
Prev close $18.52Market cap$1.1B
ConsensusStrong Buy
12-mo target$35.39 (+93.8%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)9 New Institutional Positions8 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on AKTS right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (93%)
Inst. Holders
50 funds
Inst. Value
$467.7M
Inst. Activity
9 buys / 8 sells
Insider Activity
$0.00 buy / $3.2M sell
Insider Net $
-$3.2M
SEC Reports
3
Press Releases
3
Price chart 30d -32.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 Insider
Czibere Akos sold 7,401 shares
Chief Medical Officer @ $21.03 ($155.6K)
Sep 23, 2026 Insider
Czibere Akos acquired via exercise 12,500 shares
Chief Medical Officer @ $4.95 ($61.9K)
Sep 23, 2026 Insider
Aug 15, 2026 SEC Czibere Akos sold 5,099 shares
Chief Medical Officer @ $20.19 ($103.0K)
Aktis Oncology (AKTS) saw a mixed institutional cluster in Q2 2026, with 6 buyers adding $3.9M in net new positions (led
INST-CLUSTER — Impact 4/10
Aug 13, 2026 earnings
Jul 10, 2026 SEC Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Compan
Two C-suite insiders at Aktis Oncology (COO and CMO) executed near-simultaneous option-exercise-and-sell transactions on
CLUSTER — Impact 4/10
Jun 30, 2026 Inst.
FMR LLC — TRIM
285,631 shares ($9.2M)
Jun 30, 2026 Inst.
BARCLAYS PLC — DOUBLED
151,696 shares ($4.9M)
Analyst ratings buy % +3.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
93% rate it Buy or better · 15 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 2, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Sep 9, 2026 | Oppenheimer | INITIATE | Outperform | 52% |
| Aug 19, 2026 | Wedbush | INITIATE | Outperform | 57% |
| Aug 19, 2026 | BMO Capital | INITIATE | Outperform | 53% |
| Jul 14, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Jun 16, 2026 | Raymond James | INITIATE | Strong Buy | 54% |
| Jun 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Apr 29, 2026 | William Blair | INITIATE | Outperform | 51% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 7 | 1 | 0 | 0 | 93% | |
| Aug 1, 2026 | 6 | 6 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 6 | 6 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% |
Price targets
Where 9 covering analysts think AKTS trades over the next 12 months.
$35.39 +93.8% upside Strong Buy
Current$18.26 Low$31.50 Median$35.00 High$40.00 9 analysts
$31.50$40.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 0 bearish, 1 mixed, 2 neutral · avg impact 4.0/10.Plus 3 press releases.
MIXEDINST-CLUSTER4/10
Aktis Oncology (AKTS) saw a mixed institutional cluster in Q2 2026, with 6 buyers adding $3.9M in ne
Aug 15, 2026
NEUTRALCLUSTER4/10
Two C-suite insiders at Aktis Oncology (COO and CMO) executed near-simultaneous option-exercise-and-
Jul 10, 2026
NEUTRAL8-K4/10
Aktis Oncology reported Q1 2026 financial results, highlighting a net loss of $18.3 million (vs. $15
May 11, 2026
BULLISH7/10
Aktis reported first-in-human clinical imaging and dosimetry data for AKY-2519, a B7-H3-targeted min
May 21, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 13, 2026
earnings
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on
Jul 20, 2026
ftd
FTD: AKTS — 26,704 shares ($0.7M) failed to deliver
Settlement: 20260720, Price: $24.89, FTD Value: $664,662.56, AKTIS ONCOLOGY INC COM
Jul 1, 2026
ftd
FTD: AKTS — 285,759 shares ($9.2M) failed to deliver
Settlement: 20260701, Price: $32.23, FTD Value: $9,210,012.57, AKTIS ONCOLOGY INC COM
May 27, 2026
other
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expandi
May 21, 2026
fda
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology co
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.46 | $-0.56–$-0.34 | — | -0.3% | 2↑ 2↓ | $0.0B | 7 |
| Next Q | $-0.48 | $-0.61–$-0.12 | — | -39.7% | 2↑ 1↓ | $0.0B | 7 |
| Current FY | $-1.69 | $-1.95–$-1.27 | 97.9% | -4.0% | 1↑ 3↓ | $0.0B | 8 |
| Next FY | $-2.15 | $-3.02–$-1.08 | -27.4% | -9.2% | 1↑ 3↓ | $0.0B | 8 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.458 | — |
| 7d ago | $-0.441 | -0.017 |
| 30d ago | $-0.457 | -0.001 |
| 60d ago | $-0.470 | +0.012 |
| 90d ago | $-0.482 | +0.024 |
Institutional ownership
Which big funds own AKTS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $467.7M total value (14,511,106 shares) as of 2026-Q2. Top holders: BlackRock,, WELLINGTON, RTW. Net buying activity: 9 institutions added/increased vs 8 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 2,278,358 | $73.4M | 15.7% | NEW |
| WELLINGTON MANAGEMENT GROUP LLP | 1,966,244 | $63.4M | 13.5% | NEW |
| RTW INVESTMENTS, LP | 1,592,043 | $51.3M | 11.0% | NEW |
| RA CAPITAL MANAGEMENT, L.P. | 1,314,405 | $42.4M | 9.1% | NEW |
| Jupiter Topco LLC | 1,314,267 | $42.4M | 9.1% | — |
| BAKER BROS. ADVISORS LP | 996,351 | $32.1M | 6.9% | NEW |
| VANGUARD CAPITAL MANAGEMENT LLC | 817,075 | $26.3M | 5.6% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 520,737 | $16.8M | 3.6% | — |
| STATE STREET CORP | 484,010 | $15.6M | 3.3% | — |
| a16z Capital Management, L.L.C. | 415,000 | $13.4M | 2.9% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | TRIM | 386,379 | 285,631 | -26.1% | $9.2M |
| BARCLAYS PLC | DOUBLED | 9,724 | 151,696 | +1460.0% | $4.9M |
| UBS Group AG | TRIM | 353,263 | 99,960 | -71.7% | $3.2M |
| MORGAN STANLEY | DOUBLED | 30,723 | 62,636 | +103.9% | $2.0M |
| Nuveen, LLC | DOUBLED | 24,468 | 49,816 | +103.6% | $1.6M |
| WELLS FARGO & COMPANY/MN | DOUBLED | 7,611 | 27,659 | +263.4% | $891.5K |
| RHUMBLINE ADVISERS | ADD | 21,033 | 26,945 | +28.1% | $868.4K |
| CITADEL ADVISORS LLC | TRIM | 75,000 | 25,537 | -66.0% | $823.1K |
| GOLDMAN SACHS GROUP INC | TRIM | 30,163 | 21,278 | -29.5% | $685.8K |
| DEUTSCHE BANK AG\ | ADD | 14,080 | 21,022 | +49.3% | $677.5K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
4 insiders, 18 transactions. Net -$3.2M — $0.00 bought, $3.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Czibere Akos | Chief Medical Officer | SELL | 7,401 | $21.03 | $155.6K |
| Sep 23, 2026 | Czibere Akos | Chief Medical Officer | EXERCISE | 12,500 | $4.95 | $61.9K |
| Sep 23, 2026 | Czibere Akos | Chief Medical Officer | SELL | 5,099 | $20.19 | $103.0K |
| Jul 20, 2026 | Herrmann Ken | Director | EXERCISE | 3,506 | $0.0800 | $280.48 |
| Jul 20, 2026 | Herrmann Ken | Director | EXERCISE | 1,350 | $1.91 | $2.6K |
| Jul 20, 2026 | Herrmann Ken | Director | SELL | 3,506 | $24.56 | $86.1K |
| Jul 20, 2026 | Herrmann Ken | Director | SELL | 1,350 | $24.56 | $33.2K |
| Jul 17, 2026 | Herrmann Ken | Director | EXERCISE | 3,065 | $0.0800 | $245.20 |
| Jul 17, 2026 | Herrmann Ken | Director | SELL | 3,065 | $25.21 | $77.3K |
| Jul 8, 2026 | Czibere Akos | Chief Medical Officer | EXERCISE | 50,000 | $4.95 | $247.5K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for AKTS.
Shares short
3,252,475
Settlement Sep 15, 2026
Change vs prior
+2.4%
Semi-monthly cycle
Days to cover
11.5
At avg daily volume
Of shares outstanding
≈5.8%
Estimate — not % of float
All AKTS filing & press-release reports (6)
- INST-CLUSTER reportAug 15, 2026
- CLUSTER reportJul 10, 2026
- PRESS-RELEASE reportMay 21, 2026
- 8-K reportMay 11, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportMar 30, 2026